Summary
The paper introduces FMBench, a new benchmark designed to evaluate the fairness and performance of Multimodal Large Language Models (MLLMs) in medical visual question answering (VQA) and report generation (RG) tasks. Built from the Harvard-FairVLMed dataset, which includes 10,000 fundus images paired with clinical reports and demographic data, FMBench enables performance assessments across race, gender, ethnicity, and language groups. The authors detail their process for generating QA pairs using Llama-3.1-Instruct-70B and introduce the Fairness-Aware Performance (FAP) metric to measure group performance disparities.
Strengths
- The work effectively addresses the critical gap in fairness evaluation of MLLMs, especially within the biomedical domain, where biases can have significant consequences. By facilitating fairness assessments across various demographic groups, FMBench promotes the development of more inclusive and equitable AI systems.
- The paper introduces an innovative benchmark for assessing fairness in MLLMs, focusing on important demographic categories such as race, gender, ethnicity, and language. This comprehensive approach sets a new standard for fairness evaluation in multimodal AI.
- The authors propose a new metric, FAP, which accounts for the performance of each group as well as the relative performance compared to the weighted average across all groups. This metric helps identify disparities between demographic groups relative to the overall mean.
- The paper includes a good number of baseline comparisons, incorporating both biomedical and general-domain benchmarks. Evaluating the fairness of general-domain MLLMs is also crucial, as these models are frequently repurposed for biomedical applications.
Weaknesses
- The paper lacks sufficient evaluation of biomedical multimodal models. Although the benchmark is designed for the biomedical domain, only one model (Llava-Med) trained on biomedical data is evaluated. The authors should consider including other biomedical models, such as Dragonfly-Med ([link](https://huggingface.co/togethercomputer/Llama-3.1-8B-Dragonfly-Med-v2)), to provide a more comprehensive evaluation.
- Including the performance of commercial MLLMs such as Claude and GPT could enhance the study. These models are widely used by the general public, including for biomedical inquiries. Adding their performance would strengthen the paper by offering insights into the fairness of commercial MLLMs and their application to medical tasks.
- The paper does not clearly explain how to choose the value of lambda in the FAP equation, nor does it specify which value was used for their model evaluation. Providing more details or guidelines for selecting lambda would improve clarity and reproducibility.
- The paper makes bold claims about the performance of general MLLMs based on limited evaluations. For instance, in section 5.1, the authors state: *"Surprisingly, general MLLMs such as MiniCPM and InternVL, despite not being specifically tuned for medical data, show competitive performance, even surpassing some medical-specific MLLMs. This suggests that a well-designed general MLLM can perform well on medical tasks without targeted training. Additionally, increasing model scale does not necessarily lead to performance gains, indicating that brute-force scaling is not an ideal solution for improving MLLM performance."* These claims are significant yet are drawn from evaluations on only one type of biomedical image task and a single biomedical model. Expanding the range of tasks and models evaluated would lend stronger support to these assertions.
Questions
- How did the authors control for potential hallucinations from the LLM while generating their dataset? Was manual inspection of a handful of examples done?
- What lambda value did the authors use while calculating their FAP metric? Could they also show the plot with only the second term in their FAP equation, which measures the deviation of performance of each group from the weighted mean?
- Why did the authors only consider one biomedical model in their evaluation, even though their benchmark is specifically tailored towards multimodal biomedical models?
- Have the authors considered evaluating the performance of commercial MLLMs, such as Claude and GPT, to provide insights into how these widely used models perform in terms of fairness?